Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 9/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918968 | 0.85 | GAA (0.46) | CCR5KMT2AGAAOPRM1LMNA | |
| SCHEMBL3919263 | 0.85 | OPRD1 (0.44) | OPRD1OPRK1CCR5CHRM4KMT2A | |
| SCHEMBL1800888 | 0.85 | OPRD1 (0.44) | OPRD1OPRK1CCR5CHRM4KMT2A | |
| SCHEMBL3925963 | 0.82 | GAA (0.47) | CCR5KMT2AGAALMNA | |
| SCHEMBL2935909 | 0.82 | GAA (0.41) | CCR5KMT2AGAASMN1; SMN2 | |
| SCHEMBL1799344 | 0.82 | GAA (0.41) | CCR5KMT2AGAASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1800382 | 0.81 | GAA (0.41) | CCR5KMT2AGAAMEN1 | |
| Hydrochloric Acid SCHEMBL1802741 | 0.81 | GAA (0.41) | CCR5KMT2AGAAMEN1 | |
| SCHEMBL4035139 | 0.81 | GAA (0.43) | CCR5KMT2AGAAOPRM1LMNA | |
| SCHEMBL4037470 | 0.80 | GAA (0.44) | CCR5KMT2AGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560468-B2 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2009-07-14 | — | — | US | disclosed |
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | GRUENENTHAL GMBH (DE) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015783-A1 | Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds | THPO, UGT1A8, UGT1A4 | OPRD1 403/4885OPRK1 428/4885CCR5 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.